Apps

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

New Journal

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Cipla and Qilu ink exclusive deal to sell Keytruda biosimilar in US — Sep 3, 2026Invagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.

Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.